This article is devoted to the asymptotic study of adaptive group sequential designs in the case of randomized clinical trials (RCTs) with binary treatment, binary outcome and no covariate. By adaptive design, we mean in this setting a RCT design that allows the investigator to dynamically modify its course through data-driven adjustment of the randomization probability based on data accrued so far, without negatively impacting on the statistical integrity of the trial. By adaptive group sequential design, we refer to the fact that group sequential testing methods can be equally well applied on top of adaptive designs. We obtain that, theoretically, the adaptive design converges almost surely to the targeted unknown randomization scheme. In the estimation framework, we obtain that our maximum likelihood estimator of the parameter of interest is a strongly consistent estimator, and it satisfies a central limit theorem. We can estimate its asymptotic variance, which is the same as that it would feature had we known in advance the targeted randomization scheme and independently sampled from it. Consequently, inference can be carried out as if we had resorted to independent and identically distributed (iid) sampling. In the testing framework, we obtain that the multidimensional t-statistic that we would use under iid sampling still converges to the same canonical distribution under adaptive sampling. Consequently, the same group sequential testing can be carried out as if we had resorted to iid sampling.
Introduction
The present article and its companion article (Chambaz and van der Laan, 2010b) are devoted to the asymptotic study of adaptive group sequential designs in the case of randomized clinical trials with binary treatment, binary outcome and no covariate, focusing here on its theoretical development and there on its study by simulations. Thus, the experimental unit writes as O = (A,Y) where the treatment A and the outcome Y are dependent Bernoulli random variables. Typical parameters of scientific interest are Ψ + = E(Y|A = 1) − E(Y|A = 0) (additive scale) or Ψ × = log E(Y|A = 1) − log E(Y|A = 0) (multiplicative scale, which we consider hereafter). One can interpret causally such parameters whenever one is willing to postulate the existence of a full data structure X = (X(0),X(1)) containing the two counterfactual outcomes under the two possible treatments and such that Y = X(A) and A independent of X. If so indeed, Ψ + = E(X(1)) − E(X(0)) and Ψ × = log E(X(1)) − logE(X(0)). Let us now explain what we mean by adaptive group sequential design.
The notion of adaptive group sequential designs.
By adaptive design, we mean in this setting a clinical trial design that allows the investigator to dynamically modify its course through data-driven adjustment of the randomization probability based on data accrued so far, without negatively impacting on the statistical integrity of the trial. This definition is slightly adapted from (Golub, 2006) , the introductory article to the proceedings (to which many articles cited below belong) of a workshop entitled "Adaptive clinical trial designs: Ready for prime time?" held in October 2004, and jointly sponsored by the FDA and Harvard-MIT Division of Health Science and Technology. Using the definition of prespecified sampling plans given in (Emerson, 2006) , let us emphasize that we assume that, prior to collection of the data, the trial protocol specifies: the parameter of scientific interest, and
• estimation framework: the confidence level to be used in constructing frequentist confidence intervals for the latter parameter, the related inferential method; • testing framework: the null and alternative hypotheses regarding the latter parameter, the wished type I and type II errors, the rule for determining the maximal statistical information to be accrued, the frequentist testing procedure (including conditions for early stopping).
Furthermore, we assume that the protocol specifies a user-supplied optimal unknown choice of randomization scheme: our adaptive design does not belong to the class of prespecified sampling schemes in that it targets the latter optimal unknown choice of randomization scheme, learning it based on accrued data. We focus in this article on maximum likelihood estimation and testing. The considered user-supplied optimal unknown choice of randomization scheme is that which minimizes the asymptotic variance of our maximum likelihood estimator (MLE) of the parameter of interest. This choice, known in the literature as the Neyman allocation, is interesting because minimizing the asymptotic variance of our estimator guarantees narrower confidence intervals and earlier decision to reject the null for its alternative or not. Yet , targeting this treatment mechanism in real-life clinical trials my raise ethical issues, since this may result in more patients assigned to the inferior treatment arm. But we emphasize that there is nothing special about targeting the Neyman allocation, the whole methodology applying equally well to any choice of targeted treatment mechanism. To be more specific, we could also have chosen to target that treatment mechanism which minimizes the expected number of treatment failures subject to power constraint (the optimal allocation proposed by Rosenberger, Stallard, Ivanova, Harper, and Ricks (2001) ), or any other treatment mechanism of interest (see for instance (Hu and Rosenberger, 2006, Chapter 2) or (Tymofyeyev, Rosenberger, and Hu, 2007) ). Quoting James Hung of the FDA (about design adaptation in general-see (Hung, 2006) ), our adaptive design meets clearly stated objectives, it is certainly a "more careful planning, not sloppy planning". By adaptive group sequential design, we refer to the fact that group sequential testing methods can be equally well applied on top of adaptive designs. According to Hu and Rosenberger (2006) , "The basic statistical formulation of a sequential testing procedure requires determining the joint distribution of the sequentially computed test statistics. Under response-adaptive randomization, this is a difficult task. There has been little theoretical work done to this point, nor has there been any evaluation of sequential monitoring in the context of sequential estimation procedures [i.e. targeted adaptive designs] such as the double adaptive biased coin design." These authors end their final chapter with a quote from (Rosenberger, 2002) : "Surprisingly, the link between response-adaptive randomization and sequential analysis has been tenuous at best, and this is perhaps the logical place to search for open research topics." Indeed, we determine the limit joint distribution of the sequentially computed test statistics based on our results, and provide a theoretical background to rely upon for adaptive design group sequential testing procedures. Simultaneously, a similar result is obtained in (Zhu and Hu, 2010 ) through a different approach based on the study of the limit distribution of a stochastic process defined over (0,1].
Bibliography.
The literature on adaptive designs is vast and we apologize for not including all of it. Quite misleadingly, the expression "adaptive design" has also been used in the literature for sequential testing and, in general, for designs that allow data-adaptive stopping times for the whole study (or for certain treatment arms) which achieve the wished type I and type II errors requirements when testing a null hypothesis against its alternative.
In the literature dedicated to what corresponds to our definition of adaptive design, such adaptive designs are referred to as "response-adaptive randomization" designs (see the quote from (Hu and Rosenberger, 2006) above). Of course, dataadaptive randomization schemes have a long history, that goes back to the 1930s, and we refer to (Hu and Rosenberger, 2006 , Section 1.2) and (Jennison and Turnbull, 2000, Section 17.4) to provide the reader with a comprehensive historical perspective.
The organization of the Section 1.1 illustrates the fact that we have decided to tackle separately the group sequential testing problem from the data-adaptive determination of the randomization probability in response to data collected so far-a choice justified by the fact that separating the characterization of a group sequential testing procedure from the adaptation of the randomization probability makes perfect sense from a methodological point of view. Resorting to the same organization here is more delicate, because response-adaptive treatment allocation is indebted to early studies in the context of sequential statistical analysis, such as (Armitage, 1975 , Chernoff and Roy, 1965 , Flehinger and Louis, 1971 ) among many others. However, Hu and Rosenberger (2006) manage to trace back the idea of incorporating randomization in the context of adaptive treatment allocation designs to (Wei and Durham, 1978) .
On the one hand, regarding the adaptation of the randomization probability, data-adaptive randomization schemes belong to either the "urn model" or "double adaptive biased coin" families (see the quote from (Hu and Rosenberger, 2006) above). Adaptive designs based on urn models (so called because the randomization scheme can be modeled after different ways of pulling various colored balls from an urn) notably include the seminal "randomized play-the-winner rule" from the aforementioned article (Wei and Durham, 1978) or the more recent "drop-the-loser rule" (Ivanova, 2003) . The theory of adaptive designs based on homogeneous urn models (referring to the fact that the updating rule does not evolve through time) is presented in detail in (Hu and Rosenberger, 2006, Chapter 4) , with a comprehensive bibliography. Nonhomogeneous urn models are adaptive designs based on urn models which target a randomization scheme. Also known in the literature as estimation-adjusted urn models, these adaptive designs involve updating rules of the urn which rely on the estimation of some parameters based on data accrued so far. Recently, Zhang, Hu, and Cheung (2006) established the consistency and asymptotic normality for both the randomization scheme and the estimator of the parameter of interest in this challenging framework, under weak assumptions. Targeting a specific user-supplied optimal unknown choice of randomization scheme is at the core of adaptive designs based on flipping a (data-adaptively) biased coin. More precisely, the latter targeted randomization scheme is expressed as a function f (θ ) of an unknown parameter θ of the response model, and the adaptive design is characterized by the sequence f (θ n ) which is based on updated estimates θ n of θ as the data accrue. For instance, the targeted randomization scheme we consider (namely, the minimizer of the asymptotic variance of our MLE of the parameter of interest in clinical trials with binary treatment, binary outcome and no covariate) is a function of the two marginal probabilities of success. Again, Hu and Rosenberger (2006) manage to trace back this kind of procedure to (Eisele, 1994) . A series of articles including (Rosenberger et al., 2001, Hu and Zhang, 2004b) address the theoretical study of such adaptive designs, or investigate their properties based on simulations (Hu and Rosenberger, 2003) . Overall, the most relevant references for our present article certainly are (Hu and Rosenberger, 2006 ) (already cited many times), which concerns asymptotic theory for likelihood-based estimation (not testing) based on data-adaptive randomization schemes in clinical trials, and (Zhu and Hu, 2010) . In the latter article, Zhu and Hu mainly derive the limit joint distribution of their sequentially computed test statistic and carry out a simulation study of its properties. We compare their results with ours in the appropriate sections of (Chambaz and van der Laan, 2010b) .
On the other hand, regarding the group sequential testing problem, let us emphasize that we consider the case where one starts with a large up-front commitment sample size and uses group sequential testing to allow early stopping rather than starting out with a small commitment of sample size and extending it if necessary-the latter distinction is taken from (Mehta and Patel, 2006) . Therefore, negative results obtained e.g. in Turnbull, 2003, Tsiatis and Mehta, 2003) for such procedures (inconveniently referred to as adaptive designs methods in Patel, 2006, Tsiatis and Mehta, 2003) ) that start out with a small commitment do not apply at all to our procedure. On the contrary, we can build upon the thorough understanding of group sequential methods as exposed in Turnbull, 2000, Proschan, Lan, and Wittes, 2006) , and more recently explored in (Lokhnygina and Tsiatis, 2008) .
Furthermore, there is also a rich literature on the Bayesian approach to adaptive designs. The reader is referred to (Berry and Stangl, 1996 , J., Abrams, and Myles, 2004 , Berry, 2006 , Banerjee and Tsiatis, 2006 for further details.
Finally, this article builds upon the seminal technical report (van der Laan, 2008) which paves the way to robust and efficient estimation in randomized clinical trials thanks to adaptation of the design in a variety of settings.
Forthcoming results in words.
Following the same presentation as in Section 1.1, we obtain that the adaptive design converges almost surely to the targeted unknown randomization scheme (Theorem 1), and that
• estimation framework: the MLE of the parameter of interest is a strongly consistent estimator (Theorem 1), it satisfies a central limit theorem (Theorem 2); we can estimate its asymptotic variance, which is the same as that it would feature had we known in advance the targeted randomization scheme and independently sampled from it (Theorem 2); consequently, inference can be carried out as if we had resorted to independent and identically distributed (iid) sampling; • testing framework: the multidimensional t-statistics that we would use under iid sampling still converges to the same canonical distribution under adaptive sampling (Theorem 3); consequently, the same group sequential testing can be carried out as if we had resorted to iid sampling.
Furthermore, the comprehensive simulation study that we undertake in (Chambaz and van der Laan, 2010b) validates the theory, notably showing that the confidence intervals we obtain achieve the desired coverage even for moderate sample sizes and that type I error control at the prescribed level is guaranteed, and that all sampling procedures only suffer from a very slight increase of the type II error-see (Chambaz and van der Laan, 2010b) for the details. A three-sentence take-home message is "Adaptive designs do learn the targeted optimal design and inference and testing can be carried out under adaptive sampling as they would under the targeted optimal randomization probability iid sampling. In particular, adaptive designs achieve the same efficiency as the fixed oracle design. This is confirmed by a simulation study, at least for moderate or large sample sizes, across a large collection of targeted randomization probabilities."
In essence, everything works as predicted by theory. However, theory also warns us that gains cannot be dramatic in the particular setting of clinical trials with binary treatment, binary outcome and no covariate. Nonetheless, this article and its companion article (Chambaz and van der Laan, 2010b) are important: they provide a theoretical template and tools for asymptotic analysis of robust adaptive designs in less constrained settings, which we will consider in future work. This notably includes the setting of clinical trials with covariate, binary treatment, and discrete or continuous outcome, or the setting of clinical trials with covariate, binary treatment, and possibly censored time-to-event among others. Resorting to targeted maximum likelihood estimation (van der Laan and Rubin, 2006) along with adaptation of the design provides substantial gains in efficiency.
Finally, we want to emphasize that the whole adaptive design methodology that we develop here is only relevant for clinical trials in which a substantial number of observations are available before all patients are randomized. From now on, we assume that the clinical trial's time scale permits the application of the adaptive design methodology. It must be noted that one can find in the literature some articles devoted to the study of response-adaptive clinical trials based on possibly delayed responses (see Section 7.1 in (Hu and Rosenberger, 2006) , Zhang, 2004a, Zhang, Chan, Cheung, and ). A typical sufficient condition which allows handling the possible delay is the following: the probability of the event "the outcome of the nth patient is unavailable when the (n+m)th patient is randomized" is upper-bounded by a constant times m −γ for some γ > 0.
Organization of the article.
The article is organized as follows. We define the targeted optimal design in Section 2, and describe how to adapt to it in Section 3. The asymptotic study of the MLE of the parameter of interest under adaptive design is addressed in Section 4, where we obtain that the MLE is strongly consistency and asymptotically Gaussian. In Section 5 we show how a group sequential testing procedure can be applied on top of the adaptive design methodology. In Appendix A.1 we present an important building block for consistency results. It consists of a uniform Kolmogorov strong law of large numbers for martingales sums that essentially relies on a maximal inequality for martingales. Another important building block for central limit theorems is presented in Appendix A.2, where we derive a central limit theorem for discrete martingales.
Finally, in order to ease the reading, we highlight throughout this article and its companion article (Chambaz and van der Laan, 2010b ) the most important results. We notably point out here how to construct confidence intervals and how to apply a group sequential testing procedure while targeting the optimal design and thus accruing observations data-adaptively, see the two highlights entitled 2 Balanced versus optimal treatment mechanisms 2.1 The observed data structure and related likelihood.
We consider the simplest example of randomized trials, where an observation writes as O = (A,Y), A being a binary treatment of interest and Y a binary outcome of interest. We postulate the existence of a full data structure X = (X(0),X(1)) containing the two counterfactual (or potential) outcomes under the two possible treatments. The observed data structure O = (A,X(A)) = (A,Y) only contains the outcome corresponding to the treatment the experimental unit did receive. Therefore O is a missing data structure on X with missingness variable A.
We denote the conditional probability distributions of treatment A by
We assume that the coarsening at random (abbreviated to CAR) assumption holds: for all a ∈ A = {0,1},x ∈ X = {0,1} 2 ,
We denote by G the set of such CAR conditional distributions of A given X, referred to as the set of fixed designs. In the framework of this article, (1) is equivalent to
for all a ∈ A ,x ∈ X : g ∈ G if and only if the random variables A and X are independent. We only consider such treatment mechanisms in the rest of Section 2. The distribution P X of the full data structure X has two marginal Bernoulli laws characterized by θ = (θ 0 ,θ 1 ) ∈]0,1[ 2 with θ 0 = E P X X(0) and θ 1 = E P X X(1) (the only identifiable part of P X ). Therefore, introducing X (O) = {x ∈ X : x(A) = Y} (the set of full data structure realizations compatible with O), the likelihood of O writes as
Because of the form of the likelihood, we can say that the observed data structure O is obtained under (θ ,g).
Efficient influence curve and efficient asymptotic variance
for the log-relative risk.
Say that the parameter of scientific interest is
the log-relative risk; of course, the sequel applies to other choices, such as the excess risk.
In a classical randomized trial, we would determine a fixed treatment mechanism g (therefore complying with CAR) and sample as many iid copies of O as necessary.
The theory of semiparametric statistics teaches us that the efficient influence curves for parameters θ 0 and θ 1 under (θ ,g) are respectively
. (2) Then the delta-method (and page 386 in (van der Va a r t , 1998)) implies that the efficient influence curve for parameter Ψ(θ ) under (θ ,g) writes as
so that the efficient asymptotic variance under (θ ,g) is
A relative efficiency criterion.
Defining OR(θ ) =
, the efficient asymptotic variance as a function of the treatment mechanism g is minimized at the optimal treatment mechanism characterized by
known as the Neyman allocation (Hu and Rosenberger, 2006, page 13 
where v b (θ ) denotes the efficient asymptotic variance associated with the standard balanced treatment characterized by g b (1) = 1 2 , hence the relative efficiency criterion
The definition of our relative efficiency criterion illustrates the fact that we decide to consider the balanced treatment mechanism as a benchmark. We emphasize that any fixed design could be chosen as benchmark treatment mechanism, with minor impact on the study we expose below.
It is worth noting that v b (θ ) = v ⋆ (θ ), or in other words that the so-called balanced treatment mechanism is actually optimal, if and only if θ 0 = θ 1 . In particular, there is no gain to expect from adapting the treatment mechanism in terms of type I error control when testing the null "Ψ(θ ) = 0" against its negation. In addition, the following bound involving the relative efficiency criterion on one side and the log-relative risk on the other holds:
We present in Figure 1 three curves θ 1 → R(θ ) for three different values of θ 0 . It notably illustrates that when θ 0 is small, R(θ ) can be significantly lower than 1 for values of Ψ(θ ) which are not very large. For instance, θ = ( 1 100 , 5 100 ) yields Ψ(θ ) ≃ 1.609, R(θ ) ≃ 0.868 and optimal treatment mechanism characterized by g ⋆ (θ )(1) ≃ 0.305. Were we given the optimal treatment mechanism in advance, we would obtain confidence intervals (based on the central limit theorem and Slutsky's lemma) whose widths are approximately R(θ ) ≃ 0.931 times those of the corresponding confidence intervals we would have got using the balanced treatment mechanism.
However the gain could actually be more dramatic than the previous example suggests.
Let us consider again the testing setting: we want to test the null "Ψ(θ ) = 0" against the alternative "Ψ(θ ) > 0" with type I error α and power (1 −β ) at some user-defined alternative ψ > 0. By the delta-method, we know that the MLE of Ψ(θ )
It is furthermore natural to refer to I n = n/s 2 n , the inverse of the estimated variance of Ψ n at time n, as the statistical information available at that time. Under ψ, the central limit theorem applies and teaches us that √ I n (Ψ n −ψ) converges in distribution, as n grows to infinity, to the standard normal distribution.
Deciding to reject the null if √ I n Ψ n ≥ ξ 1−α yields a test with asymptotic type I error α. In order to ensure that its asymptotic power at alternative ψ is (1 −β ), it is sufficient that n = inf t ≥ 1 :
I max being the so-called maximum committed information.
For n large enough, I n ≃ n/v b (θ ) if we use the balanced treatment mechanism, while I n would have been approximately equal to n/v ⋆ (θ ), had we used the optimal treatment mechanism. Substituting bluntly n/v b (θ ) or n/v ⋆ (θ ) to I n in (6), we see that the ratio of the testing times n b (using the balanced treatment mechanism) and n ⋆ (using the optimal one) satisfies
the relative efficiency criterion. In other words, were we given the optimal treatment mechanism in advance, we would in average need to sample R(θ ) ∈ ( 1 2 ,1) times the number of observations required when using the balanced treatment mechanism. In the previous example where θ = ( 1 100 , 5 100 ), setting α = 0.05, β = 0.1 and the alternative parameter ψ = Ψ(θ ) ≃ 1.609 > 0, the maximal committed information is I max ≃ 3.306, n ⋆ ≃ 676.901 and n b ≃ 780.248.
In summary, resorting to the balanced treatment mechanism may be a very poor (inefficient) choice. Since the optimal treatment mechanism g ⋆ can be learned from the data, why not use it? Once again, we emphasize that there is nothing special about targeting this specific treatment mechanism. One could have also chosen to target that treatment mechanism which minimizes the expected number of failures subject to power constraint (Rosenberger et al., 2001) .
Of course, targeting the optimal treatment mechanism on the fly implies losing independence between successive observations, making the study of the design more involved. However, we present and study here such a methodology. It is built on the seminal technical report (van der Laan, 2008) .
Targeting the optimal design
In this section, we describe how we carry out the adaptation of the sampling scheme. For simplicity's sake, the randomization probability is updated at each step (i.e. each time a new observation is sampled). However, it is important to understand that all our results (and their proofs) still hold when adaptation only occurs once c new observations are accrued, where c is a pre-determined integer. In this view, we use c = 1 in the whole article as well as in the companion article (Chambaz and van der Laan, 2010b)-although our R code can handle the general case.
Adaptive coarsening at random assumption.
We denote by
the treatment assignment, full data structure, outcome, and observation for experimental unit i. Whereas X 1 ,...,X n are assumed iid, the random variables A 1 ,...,A n are not independent anymore since we want to adapt the treatment mechanism based on past observations. Defining
and for every i = 0,...,n (with convention A n (0) = X n (0) = O n (0) = / 0), let g n (·|X n ) denote the conditional distribution of the design settings A n given the full data X n : by the chain rule,
hence the additional notation
In this new setting, we state the following adaptive counterpart of the CAR assumption (1): for all 1
With obvious convention, the new adaptive CAR assumption also writes as
for all 1 ≤ i ≤ n, a ∈ A n , x ∈ X n ; it states that for each i A i is conditionally independent of the full data X n given the observed data O n (i−1) for the first (i−1) experimental units and the full data X i for the ith experimental unit, and in addition that the conditional probability of A i = a i given X i and O n (i − 1) actually only depends on the observed part X i (a i ) and O n (i − 1). In particular, (7) reduces to
3.2 Data generating mechanism for adaptive design and likelihood.
Given the available data O n (i − 1) = (O 1 ,...,O i−1 ) at step i, one first draws X i from P X independently of X n (i−1), then one calculates the conditional distribution g i (·|X i ,O n (i − 1)) and one samples A i given X i from it, the next observation finally
(the set of those realizations x of X n compatible with O n ), then
the third and fourth equalities being derived from the adaptive CAR equality (9) and from independence of X 1 ,...,X n respectively. Thus, the likelihood remarkably factorizes into the product of a θ -factor and a g n -factor. Thanks to the form of the likelihood, we can say that O n is obtained under (θ ,g n ). For convenience, we also write sometimes that O n is obtained under g n -adaptive sampling scheme without specifying the parameter θ . Likewise, we later refer to data obtained under iid g b -balanced or under iid g ⋆ -optimal sampling schemes.
Strategy.
2 as long as no relevant observation is available). Thanks to the form of the log-likelihood exhibited in (10) and as soon as
as if we used a deterministic treatment mechanism (and observations were iid).
These empirical means yield plug-in estimates σ 2 i (a) = θ i,a (1 − θ i,a ) of σ 2 (θ )(a), as well as plug-in estimates of the optimal treatment mechanism g ⋆ (θ ) introduced in (4), characterized by g s 1 (1|O n (0)) = 1 2 and for i ≥ 1,
(sometimes abbreviated to g s i+1 (1)), hence a first adaptive CAR treatment mechanism g s n = (g s 1 ,...,g s n ). Another interesting choice is also considered here, which we characterize iteratively by g 1 (1|O n (0)) = 1 2 and for i ≥ 1,
This alternative choice aims at obtaining a balance between the two treatments which, at experiment i, closely approximates g ⋆ (θ ), in the sense that
(1), the current best guess. This second definition is more aggressive in the pursuit of the optimal treatment mechanism, as it tries to compensate on the fly for early sub-optimal sampling.
A technical condition was actually left aside in the definition of g s n . Because we want to exclude the possibility that the adaptive design stops a treatment arm with probability tending to 1, we impose that g i+1 (1|O n (i)) ∈ [δ ;1−δ ] for a small δ > 0 (such that δ < min a∈A g ⋆ (θ )(a) and 1 −δ > max a∈A g ⋆ (θ )(a)) by letting g ⋆ 1 (1|O n (0)) = 1 2 and for i ≥ 1,
(sometimes abbreviated to g ⋆ i+1 (1)), thus characterizing the adaptive CAR treatment mechanism g ⋆ n = (g ⋆ 1 ,...,g ⋆ n ). Similarly, we substitute g ⋆ i (1) to g s i (1) and allow γ to vary in [δ ,1−δ ] only in (12), yielding another adaptive CAR treatment mechanism g a n (where the superscript a stands for aggressive). The same kind of δ -thresholding, which makes perfect sense from an applied point of view too, was already suggested in (Tymofyeyev et al., 2007) .
It is worth noting that Hu, Zhang, and He (2009) address a very interesting problem that we do not consider here: they show how to target the user-supplied treatment mechanism in such a way that the Cramer-Rao lower bounds on the allocation variances are achieved, thanks to a clever generalization of the celebrated Efron's biased coin design (Efron, 1971) . Of course, resorting to the same kind of strategy would be possible here, but is outside the scope of this article.
In the rest of this article, we investigate theoretically the properties of the data-adaptive designs based on g ⋆ n only. The theoretical study is backed by the simulation carried out in the companion article (Chambaz and van der Laan, 2010b) , where g a n is also considered.
Asymptotic study
We address in this section the asymptotic statistical study of the method presented in the previous section. We state strong consistency results then a central limit theorem, from which we derive a rule for constructing confidence intervals.
The following consistency result holds, which teaches us that the method does learn what is the optimal design. Its proof mainly relies on Theorem 6, and we refer to (Chambaz and van der Laan, 2010a) for the details.
, for the adaptive CAR treatment mechanism g ⋆ n characterized by (13) . Then θ n converges almost surely to θ . Consequently, Ψ n is a strongly consistent estimate of Ψ(θ ) and g ⋆ n converges to the optimal design g ⋆ (θ ) in the sense that g ⋆ n (1) and
) both converge almost surely to g ⋆ (θ )(1).
In order to provide statistical inference, we need now to establish that the vector √ n(θ n −θ ) converges in distribution so that one can construct confidence intervals for θ and come up with valid testing procedures. The following central limit theorem actually holds. Its proof mainly involves the multivariate central limit theorem stated in Theorem 8 and resorting to the delta-method, see (Chambaz and van der Laan, 2010a) for the details.
Theorem 2. Let θ n be the MLE of θ
) and IC(θ ,g ⋆ (θ )) be as defined in (2) and (3) 
Furthermore,
centered Gaussian distribution with covariance matrix
The latter is consistently estimated with its empirical counterpart
as if the sampling was iid. Thus under (θ ,g ⋆ n ), we also have
and convergence in distribution of √ n(Ψ n − Ψ(θ )) to a centered Gaussian distribution with variance v ⋆ (θ ), the optimal efficient asymptotic variance. The latter is finally consistently estimated with either v ⋆ (θ n ) or
) 2 as if sampling was iid.
We wish to construct a confidence interval for Ψ(θ ) based on O n sampled under (θ ,g ⋆ n ). Let us denote by s 2 n either consistent estimates of v ⋆ (θ ) based on O n as introduced in Theorem 2, and let ξ 1−α/2 be the (1 − α/2)-quantile of the standard normal distribution. By the latter theorem, Highlight 1 (pointwise estimation and confidence interval). In view of Theorems 1 and 2, the estimator Ψ n of Ψ(θ ) obtained under (θ ,g ⋆ n )-adaptive sampling scheme is strongly consistent, the estimated probability of being treated g ⋆ n (1) also converging almost surely to the optimal probability of being treated g ⋆ (θ )(1). In addition, the confidence interval
has asymptotic coverage (1 −α).
This theoretical result is validated with simulations in Section 3 of the companion article (Chambaz and van der Laan, 2010b) , focusing on the empirical distribution of the MLE in Section 3.2, on the empirical coverage guaranteed by the confidence intervals in Section 3.3 and on their empirical widths in Section 3.4. Moreover, an illustrating example is developed in Section 3.5 of (Chambaz and van der Laan, 2010b) .
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The International Journal of Biostatistics, Vol. 7 [2011] Obviously, the sequence of estimators (Ψ n ) n≥1 can be used to carry out the test of the null "Ψ(θ ) = ψ 0 " against its unilateral alternative "Ψ(θ ) > ψ 0 " for some ψ 0 ∈ R. We build in this section a group sequential testing procedure, that is a testing procedure which repeatedly tries to make a decision at intervals rather than once all data are collected, or than after every new observation is obtained (such a testing procedure would be said fully sequential). We refer to Turnbull, 2000, Proschan et al., 2006) for a general presentation of group sequential testing procedures.
5.1
The targeted optimal design group sequential testing procedure.
Formal description of the targeted optimal design group sequential testing procedure.
We wish to test the null "Ψ(θ ) = ψ 0 " against "Ψ(θ ) > ψ 0 " with asymptotic type I error α and asymptotic type II error β at some ψ 1 > ψ 0 . We intend to proceed group sequentially with K ≥ 2 steps, and we wish to rely on a multidimensional t-statistic of the form
where each N k is a carefully chosen (random) sample size and where s 2 n estimates the asymptotic variance of
To this end, let 0 < p 1 < ... < p K = 1 be increasingly ordered proportions. Consider the α-spending and β -spending strategies (α 1 ,...,α K ) and (β 1 ,...,β K ), i.e. K-tuples of positive numbers such that ∑ 
..,Z K ) follow the centered Gaussian distribution with covariance matrix C = ( p k∧l /p k∨l ) k,l≤K and let us assume that there exists a unique value I > 0, the so-called maximum committed information from now on denoted by I max , such that there exist a rejection boundary (a 1 ,...,a K ) and a futility bound- 
Note that the closer ψ 1 is to ψ 0 , the larger is I max (actually, ψ 1 → (ψ 1 − ψ 0 ) √ I max is both upper bounded and bounded away from zero). Heuristically, the closer ψ 1 is to ψ 0 , the more difficult it is to decide between the null and its alternative while preserving the required type II error at ψ 1 , the more information is needed to proceed. In this setting, it is natural to refer to the inverse of the variance of Ψ n as an amount of statistical information collected so far. The latter information writes as n/s 2 n , notably making clear that the product s 2 n I max and number of observations n are on the same scale. In this spirit, let us finally define for each k ≤ K
max is large, then N k tend to be large too. The targeted optimal design group sequential testing rule finally writes as follows: starting from k = 1, if˜T k ≥ a k then reject the null and stop accruing data, if˜T k ≤ b k then fail rejecting the null and stop accruing data, if b k <˜T k < a k then set k ← k + 1 and repeat.
If (˜T 1 ,...,˜T K ) had the same distribution as (Z 1 ,...,Z K ), then the latter rule would yield a testing procedure with the required type I error and type II error at the specified alternative parameter.
The merit is clear of targeting the fixed design g ⋆ (θ ) that makes the estimate Ψ n have the optimal (i.e. smallest) asymptotic variance, the random variables N k (i.e. successive number of observations required for testing) then being, at least informally, stochastically smaller than they would have been had another fixed design been used (or targeted).
Carrying out the targeted optimal design group sequential testing procedure.
We wish to test the null "Ψ(θ ) = ψ 0 " against "Ψ(θ ) > ψ 0 " with asymptotic type I error α and asymptotic type II error β at some ψ 1 > ψ 0 . We intend to proceed group sequentially with K ≥ 2 steps.
18
The International Journal of Biostatistics, Vol. 7 [2011] 
We investigate the behavior of this group sequential testing procedure from a theoretical perspective in Section 5.2. The procedure is studied by simulations in Section 4 of the companion article (Chambaz and van der Laan, 2010b) , focusing on empirical type I and type II errors in Section 4.2 and on empirical sample sizes at decision in Section 4.3.
Asymptotic study of the targeted optimal design group se-
quential testing procedure powered at local alternatives.
In order to tackle the asymptotic study of the targeted optimal design group sequential testing procedure, we resort to contiguity arguments. According to (van der Va a r t , 1998, Chapter 6), "contiguity arguments are a technique to obtain the limit distribution of a sequence of statistics under underlying laws Q n from a limiting distribution under laws P n ." Here the laws P n describe a null distribution under investigation (the distribution of the test statistic under (θ ,g ⋆ n )), and the laws Q n correspond to an alternative hypothesis.
Proving the validity of the targeted optimal design group sequential testing procedure (as defined in Section 5.1) powered at local alternatives is outside the scope of this article. We rather consider a slightly simpler version where the random N k are replaced by deterministic n k . We conjecture that the theorem we prove in the simpler deterministic sample sizes context can be extended to the random sample sizes context. The simulation study that we undertake in Section 4 of the companion article (Chambaz and van der Laan, 2010b) confirms the conjecture.
Once again, let 0 < p 1 < ... < p K = 1 be increasingly ordered proportions for some integer K ≥ 2, and define n k = ⌈np k ⌉ (the smallest integer not smaller than np k ) for each k ≤ K. We wish to the test the null against its alternative based on the multidimensional t-statistic
(s 2 n estimates the asymptotic variance of √ n(Ψ n − Ψ(θ )) under (θ ,g ⋆ n )-see Theorem 2). Before going any further, we state a crucial theorem which describes how the test statistic converges towards the so-called canonical distribution. A similar result is obtained by Zhu and Hu (2010) through a different approach based on the study of the limit distribution of a stochastic process defined over (0, 1] .
,T K ) converges in distribution, as n tends to infinity, to the centered Gaussian distribution with covariance matrix
..,T K ) converges in distribution, as n tends to infinity, to the Gaussian distribution with mean µ(h) and covariance matrix C .
Say we want to perform a test such with asymptotic type I error α and asymptotic power (1 − β ) at the limit of the sequence of contiguous parameters (ψ n ) n≥n 0 , i.e. such that (a) the probability of rejecting the null for its alternative under (θ ,g ⋆ n ), and (b) the probability of failing to reject the null for its alternative under (θ h/ √ n ,g ⋆ n ) converge (as n tends to infinity) towards α and β , respectively. Let us consider the α-spending and β -spending strategies (α 1 ,...,α K ) and (β 1 ,...,β K ). It is usually assumed that the next lemma holds:
Given such rejection and futility boundaries, we proceed as follows: starting from k = 1, if T k ≥ a k then reject the null and stop accruing data, if T k ≤ b k then fail rejecting the null and stop accruing data, if b k < T k < a k then set k ← k + 1 and repeat Theorem 3 and Lemma 4 teach us that the group sequential testing procedure described above satisfies the requirements on stepwise type I and type II error control, once h is replaced with εh (which actually corresponds to a shift in n in the definition of the sequence of contiguous alternatives (θ h/ √ n ) n≥n 0 ).
Proof of Theorem 3.
Theorem 3 is a corollary of the following Lemma 5. Denote by Λ n the log-likelihood ratio of the (θ h/ √ n ,g ⋆ n ) experiment with respect to the (θ ,g ⋆ n ) experiment, as defined in Theorem 3. There exists a constant τ 2 > 0 such that, under (θ ,g ⋆ n ), the vector ( 
In particular, the (θ h/ √ n ,g ⋆ n ) and (θ ,g ⋆ n ) experiments are mutually contiguous.
It is easy to obtain the limiting distribution of (T 1 ,...,T K ) under (θ ,g ⋆ n ) from Lemma 5. Le Cam's third lemma solves the problem of obtaining the limiting distribution of (T 1 ,...,
from the convergence under (θ ,g ⋆ n ) exhibited in Lemma 5. The second limiting distribution is still Gaussian, has the same asymptotic covariance matrix as under (θ ,g ⋆ n ), but differs by its asymptotic mean which is no longer 0.
Proof of Theorem 3. By the continuous mapping theorem, we readily obtain from Lemma 5 the convergence in distribution under (θ ,g ⋆ n ) of
to the centered Gaussian distribution with covariance matrix
Then Slutsy's lemma straightforwardly yield the first convergence (i).
Regarding (ii), we first invoke Lemma 5 and Le Cam's third lemma (see Example 6.7 in (van der Va a r t , 1998)) in order to obtain that, under
) converges in distribution to the Gaussian distribution with mean v ⋆ (θ )µ(h) and covariance matrix
In addition, the
. We apply again Slutsky's lemma in order to obtain the second convergence (ii).
Proof of Lemma 5. Let us consider first the log-likelihood ratio of the experiments
First, we observe that, since L 2 is bounded (and measurable),
by virtue of Theorem 1. In summary, we obtain that
. Second, we define Z i = (1l {i ≤ n 1 },...,1l {i ≤ n K }) and we introduce the bounded (and measurable) function f such that
Let us show that
The entries of W n take one of the following forms:
a) (see Theorem 1) implies its convergence in L 1 norm to the same limit;
, from which it follows that 1 n EB n = p k∧l 
n EC n = τ 2 +o(1), and 1 n C n − 1 n EC n = o P (1) for the same reasons as above.
Those calculations notably teach us that, setting m = (h 1 −h 0 )(p 1 ,...,p K ) and
Is Σ a positive definite covariance matrix? Well, Σ 0 is a positive definite covariance matrix (that of the vector (B p 1 ,...,B p K ) where (B t ) t≥0 is a standard Brownian motion), hence the symmetric matrix Σ is a positive definite covariance matrix if and only if its determinant det(Σ) > 0. Subtracting (h 1 − h 0 )/v ⋆ (θ ) times the Kth row of Σ to its last row, we get that det
In summary, Σ is a positive definite covariance matrix, the conditions of Theorem 8 are met, and therefore
converges in distribution to the centered Gaussian distribution with covariance matrix Σ.
Let us define the diagonal matrices ∆ n = diag( n/n 1 ,..., n/n K ,1) and ∆ = diag(1/ √ p 1 ,...,1/ √ p K ,1); obviously, ∆ n = ∆ + o(1), √ nM n ∆ n = √ nM n ∆ + o P (1). Invoking (17) This entails the convergence in distribution of ( √ n 1 (Ψ n 1 − Ψ(θ )),..., √ n K (Ψ n K − Ψ(θ )),Λ n ) under (θ ,g ⋆ n ) to the Gaussian distribution with mean (0,...,0,− 1 2 τ 2 ) and covariance matrix ∆Σ∆. Simple calculations finally reveal that ∆Σ∆ equals the positive definite covariance matrix given in the lemma.
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The International Journal of Biostatistics, Vol. 7 [2011] We have studied in this article the theoretical properties of a new adaptive group sequential design methodology for randomized clinical trials with binary treatment, binary outcome and no covariate (the experimental unit writes as O = (A,Y) ∈ {0,1} 2 , A being the assigned treatment and Y the corresponding outcome). In the companion article (Chambaz and van der Laan, 2010b) , the study is carried out by simulations.
Prior to accruing data, the trial protocol must specify Ψ, the parameter of interest. Regarding the estimation of Ψ, the trial protocol must specify the confidence level to be used in constructing the confidence interval. Regarding the testing of Ψ, the trial protocol must specify the null and alternative hypotheses, the wished type I error, the alternative parameter at which the test is to be powered and the related wished type II error. If the investigator wants to resort to a group sequential testing procedure, then the trial protocol must also specify the number of intermediate tests, the related proportions, the α-and β -spending strategies (then the maximum committed information, rejection and futility boundaries are fully determined). Finally, the trial protocol must specify the (fixed) targeted design. We decided to focus in this article on the log-relative risk Ψ = log E(Y|A = 1) − log E(Y|A = 0) and on that design g ⋆ which minimizes the asymptotic variance of the MLE of Ψ. Other choices can be treated likewise.
The methodology is adaptive in the sense that the estimator of g ⋆ , which appears to be strongly consistent (see Highlight 1), is alternatively used in the process of accruing new data, then updated and so on. The resulting MLE of Ψ, Ψ n , is strongly consistent (see Highlight 1). It satisfies a central limit theorem, and performs as well (in terms of asymptotic variance) as its counterpart under iid sampling using g ⋆ itself (see Highlight 1). Therefore, one easily constructs confidence intervals which are as narrow as the intervals one would get, has one known in advance g ⋆ and used it to sample independently data (see Highlight 1). Those theoretical results are validated with simulations in the companion article (Chambaz and van der Laan, 2010b) .
Furthermore, we explain how a group sequential testing procedure can be equally well applied on top of the adaptive sampling methodology (see Highlight 2). An accompanying theoretical result validates the adaptive group sequential testing procedure in the context of contiguous null and alternative hypotheses. It is supported by the simulations undertaken in the companion article (Chambaz and van der Laan, 2010b) .
As stated in the abstract, a three-sentence take-home message is "Adaptive designs do learn the targeted optimal design and inference and testing can be carried out under adaptive sampling as they would under the targeted optimal randomiza-tion probability iid sampling. In particular, adaptive designs achieve the same efficiency as the fixed oracle design. This is confirmed by a simulation study presented in the companion article (Chambaz and van der Laan, 2010b) , at least for moderate or large sample sizes, across a large collection of targeted randomization probabilities." In essence, everything works as predicted by theory. However, theory also warns us that gains cannot be dramatic in the particular setting of clinical trials with binary treatment, binary outcome and no covariate. Nonetheless, this article and its companion article (Chambaz and van der Laan, 2010b) are important: they provide a theoretical template and tools for asymptotic analysis of robust adaptive designs in less constrained settings, which we will consider in future work. This notably includes the setting of clinical trials with covariate, binary treatment, and discrete or continuous outcome, or the setting of clinical trials with covariate, binary treatment, and possibly censored time-to-event among others. Resorting to targeted maximum likelihood estimation (van der Laan and Rubin, 2006) along with adaptation of the design provides substantial gains in efficiency.
